These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 978134)

  • 41. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.
    Vuagnat BB; Mach J; Le Doussal JM
    Mol Immunol; 2000 Jun; 37(8):467-78. PubMed ID: 11090881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
    Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complement: activation, consequences, and control.
    James K
    Am J Med Technol; 1982 Sep; 48(9):735-42. PubMed ID: 6215861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A molecular basis of activation of the alternative pathway of human complement.
    Austen KF; Fearon DT
    Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure and function of complement C5 convertase enzymes.
    Pangburn MK; Rawal N
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1006-10. PubMed ID: 12440962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins.
    Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1978 Dec; 148(6):1722-7. PubMed ID: 722244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The alternative pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
    [No Abstract]   [Full Text] [Related]  

  • 54. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
    Day NK; Schreiber RD; Götze O; Müller-Eberhard HJ
    Scand J Immunol; 1976; 5(6-7):715-20. PubMed ID: 981969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement.
    Rawal N; Rajagopalan R; Salvi VP
    J Biol Chem; 2008 Mar; 283(12):7853-63. PubMed ID: 18204047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
    Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
    Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
    Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
    Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Babesia rodhaini: requirement of complement for penetration of human erythrocytes.
    Chapman WE; Ward PA
    Science; 1977 Apr; 196(4285):67-70. PubMed ID: 841340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE; Balber AE
    Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
    Vogt W; Schmidt G; Dieminger L; Lynen R
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.